MAIA Biotechnology Inc. (MAIA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, MAIA Biotechnology Inc. (NYSE: MAIA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.10 (-6.78% 1D, market cap $72.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MAIA ranks #327 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MAIA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LFVN (Lifevantage Corporation (Delaware)) holds a B+ grade (76/100 RQD, P/E 7.5x, ROIC 29.2%, cap $73.9M) and TELO (Telomir Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $71.0M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
Per MAIA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001878313), MAIA Biotechnology Inc. generated $0 in revenue, -$22.4M in net income, and -$18.8M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 45.2 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±10.6% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While MAIA currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.24) and Max Pain ($1.16) forces dealer call-delta covering toward $3.35.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
MAIA Biotechnology Inc. (MAIA) dropped -6.78% to $1.10, trading at 10% of its 52-week range ($0.87 – $3.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Dealroom report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MAIA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MAIA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, MAIA Biotechnology Inc. (MAIA) ranks #327 by composite RQD confidence (48/100, grade D) and #703 by equity capitalization ($72.9M). Within this direct 5-issuer industry benchmark cohort, LFVN leads on earnings valuation at 7.5x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with MAIA at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MAIA
ACTIVE
MAIA Biotechnology Inc. | D | 48/100 | — | — | -35.0% | -6.78% | $72.9M | Benchmark Subject |
| LFVN Lifevantage Corporation (Delaware) | B+ | 76/100 | 7.5x | 80.4% | 29.2% | +0.17% | $73.9M | /lfvn-vs-maia → |
| TELO Telomir Pharmaceuticals Inc. | E | 34/100 | — | — | -35.0% | -3.01% | $71.0M | /telo-vs-maia → |
| ACRV Acrivon Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -5.68% | $75.4M | /acrv-vs-maia → |
| CING Cingulate Inc. | D- | 36/100 | — | — | -35.0% | -4.05% | $75.5M | /cing-vs-maia → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), MAIA Biotechnology Inc. (MAIA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$22.4M, operating cash flow of -$18.8M, and free cash flow of -$18.8M (-20.0% YoY). On the balance sheet, MAIA closed FY2025 with $9.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$22.4M | -$18.8M | -$18.8M | $9.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$23.3M | -$15.7M | -$15.7M | $10.2M | — |
As of 2026-11-02, MAIA Biotechnology Inc. (NYSE: MAIA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.10 (-6.78% 1D, market cap $72.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MAIA ranks #327 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MAIA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LFVN (Lifevantage Corporation (Delaware)) holds a B+ grade (76/100 RQD, P/E 7.5x, ROIC 29.2%, cap $73.9M) and TELO (Telomir Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $71.0M). Among the 5-stock peer group, LFVN leads on earnings multiple (7.5x) while LFVN leads on capital efficiency (29.2% ROIC).
Per MAIA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001878313), MAIA Biotechnology Inc. generated $0 in revenue, -$22.4M in net income, and -$18.8M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MAIA last traded at $1.10 (-6.78% on volume of 313,663 shares), positioning the stock -11.29% below its 50-day simple moving average ($1.24) and -24.66% below its 200-day simple moving average ($1.46). Across its 52-week range of $0.87 to $3.19, MAIA sits at the 9.9% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($1.00 to $1.22).
Why MAIA Stock dropped -6.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, MAIA scores 48 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 15/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillars are the cash engine and insider conviction, which together indicate that the reported business is not yet generating cash and that insider flow offers limited support. The strongest relative pillar is macro fit, which reflects a beta of 1.0 but does not offset the fundamental weakness. For a prospective investor, the rating frames the stock as one where the upside case rests almost entirely on future clinical and corporate developments rather than on current economics. Valuation cannot be anchored to earnings, since P/E and EPS are not available in source data, and the zero FCF yield means there is no present cash return to support the price. The 52-week range of $0.87 to $3.19 against a current price of $1.13 illustrates high price volatility relative to the company's disclosed fundamentals.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $-24.3M | $-22.4M | N/A | $-18.8M | $0.0M | N/A |
| FY 2024 (filed 2024-12-31) | $0.0M | $-17.0M | $-23.3M | N/A | $-15.7M | $0.0M | N/A |
Per the SEC financials, reported revenue is $0.0M in both periods, with operating losses of $-24.3M in FY 2025 and $-17.0M in FY 2024. Net margin, gross margin, and operating margin are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3 out of 9, and Debt/Equity is 0.5. The reported cash balance is $0.0M in both periods, and debt is listed as N/A, so balance sheet posture cannot be fully characterized from the financial table alone.
Per the recent news wire, the principal catalyst is a headline reporting patient enrollment milestones in ongoing Phase 2 and pivotal Phase 3 non-small cell lung cancer trials, carried by multiple outlets within the last several hours. A separate report flagged MAIA among premarket movers on Nov. 2, 2026, marked as a catalyst item. Several items are general quote-page or seasonal-return listings with limited analytical content. A Benzinga headline references insider buying in biotech names, which is relevant to the insider pillar but is not quantified in the holders data. Risk watch items: the news wire contains no information on trial readouts, regulatory timelines, or financing. Per the Butterfly Supply-Chain Graph, no proprietary signals are present; supply chain: NONE.
Real-time company headlines, analyst actions, and sector developments for MAIA Biotechnology Inc. (MAIA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Dealroom report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MAIA Biotechnology Inc. (MAIA) market action, institutional positioning, and fundamental catalysts.
Welcome to the MAIA (MAIA Biotechnology Inc.) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on MAIA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless MAIA Biotechnology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on MAIA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.18 (52-wk range $0.99 - $1.25), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).